Alterity Therapeutics (ATHE) Competitors $5.00 -0.03 (-0.50%) Closing price 03:57 PM EasternExtended Trading$5.00 -0.01 (-0.20%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHE vs. SXTC, KRRO, CRBU, CCCC, TVGN, SLS, ENTA, LFVN, CYBN, and ACTUShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include China SXT Pharmaceuticals (SXTC), Korro Bio (KRRO), Caribou Biosciences (CRBU), C4 Therapeutics (CCCC), Tevogen Bio (TVGN), SELLAS Life Sciences Group (SLS), Enanta Pharmaceuticals (ENTA), Lifevantage (LFVN), Cybin (CYBN), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry. Alterity Therapeutics vs. Its Competitors China SXT Pharmaceuticals Korro Bio Caribou Biosciences C4 Therapeutics Tevogen Bio SELLAS Life Sciences Group Enanta Pharmaceuticals Lifevantage Cybin Actuate Therapeutics Alterity Therapeutics (NASDAQ:ATHE) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Which has stronger valuation and earnings, ATHE or SXTC? China SXT Pharmaceuticals has higher revenue and earnings than Alterity Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity TherapeuticsN/AN/A-$12.54MN/AN/AChina SXT Pharmaceuticals$1.74M98.69-$3.30MN/AN/A Which has more risk & volatility, ATHE or SXTC? Alterity Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Do analysts recommend ATHE or SXTC? Alterity Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 139.76%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Alterity Therapeutics is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ATHE or SXTC more profitable? Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A China SXT Pharmaceuticals N/A N/A N/A Does the media refer more to ATHE or SXTC? In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 2 mentions for Alterity Therapeutics. China SXT Pharmaceuticals' average media sentiment score of 1.27 beat Alterity Therapeutics' score of 0.93 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive China SXT Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in ATHE or SXTC? 2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryChina SXT Pharmaceuticals beats Alterity Therapeutics on 6 of the 10 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHE vs. The Competition Export to ExcelMetricAlterity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.39M$3.09B$5.74B$9.78BDividend YieldN/A2.26%4.40%4.04%P/E RatioN/A21.2230.8326.39Price / SalesN/A206.90382.9086.63Price / CashN/A44.2437.7259.11Price / Book4.818.0710.106.62Net Income-$12.54M-$54.08M$3.26B$265.42M7 Day Performance-0.50%3.94%3.90%3.58%1 Month Performance-23.59%3.02%3.73%0.46%1 Year Performance222.90%6.84%37.68%19.41% Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHEAlterity Therapeutics2.6253 of 5 stars$5.01-0.5%$12.00+139.8%+271.7%$44.39MN/A0.0010News CoveragePositive NewsGap UpSXTCChina SXT Pharmaceuticals0.5818 of 5 stars$1.59-0.6%N/A-78.0%$185.64M$1.74M0.0090News CoverageKRROKorro Bio1.2024 of 5 stars$19.72-2.7%$86.83+340.3%-58.7%$185.19M$6.28M-2.0270CRBUCaribou Biosciences2.6549 of 5 stars$1.87-5.6%$6.67+256.5%-9.5%$184.38M$9.99M-1.05100Analyst UpgradeCCCCC4 Therapeutics1.7799 of 5 stars$2.86+16.3%$8.00+179.7%-62.9%$175.08M$35.58M-1.81150High Trading VolumeTVGNTevogen Bio3.8485 of 5 stars$0.96+1.6%$10.00+937.6%+69.5%$174.39MN/A0.003Positive NewsSLSSELLAS Life Sciences Group2.9083 of 5 stars$1.73+6.1%$7.00+304.6%+37.9%$171.63M$1M-5.4110ENTAEnanta Pharmaceuticals3.6443 of 5 stars$8.17+2.1%$21.67+165.2%-35.0%$171.02M$64.81M-1.89160LFVNLifevantage4.025 of 5 stars$13.69+1.5%$30.50+122.8%+46.3%$169.81M$222.35M19.84260News CoveragePositive NewsCYBNCybin2.362 of 5 stars$6.92-2.0%$85.00+1,128.3%N/A$166.55MN/A-1.5850News CoverageACTUActuate TherapeuticsN/A$8.25+1.6%$20.50+148.5%+2.9%$166.22MN/A0.0010News CoverageAnalyst Forecast Related Companies and Tools Related Companies SXTC Competitors KRRO Competitors CRBU Competitors CCCC Competitors TVGN Competitors SLS Competitors ENTA Competitors LFVN Competitors CYBN Competitors ACTU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHE) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access